Vasthera Co., Ltd

[Not Yet Scheduled]
Vasthera is a start-up preclinical company that develops innovative drug candidates treating arterial diseases such as Pulmonary Arterial Hypertension(PAH), In-stent Restenosis, Angina/Cardiac Infarction, Atherosclerosis, and Heart failure.

We have our own proprietary platform, so-called “STEM (Synthetic Thiol Enzyme Mimetic)” technology, to discover the small-molecule therapeutics that can replace the natural redox enzyme named Peroxiredoxin (PRDX). The STEM technology provides a library of new drug candidates that can be applied to treat various diseases where the PRDX enzyme is inactivated or silenced. The related fundamental science has earlier published in Science, Molecular Cell and Circulation.

Our first pipeline from the STEM technology targets PAH and enters the phase I trial early next year. the second pipeline targets triple-negative breast cancer and is currently under preclinical development. Thus, we are looking for any partners who could make research coll
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
VTA-004(PAH)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1